USANA HEALTH SCIENCES INC USNA
NYSE · XNYS · stock · Medicinal Chemicals & Botanical Products
Chart by TradingView
6/9
Piotroski F — financial health
7.37
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $925.3M | $10.8M | $724.4M | $8.5M | $533.1M |
| 2024 | $854.5M | $42.0M | $693.3M | $50.9M | $532.1M |
| 2023 | $921.0M | $63.8M | $744.3M | $56.1M | $497.2M |
| 2022 | $998.6M | $69.3M | $804.7M | $93.5M | $434.5M |
| 2022 | $1.2B | $116.5M | $968.6M | $108.5M | $395.1M |
| 2021 | $1.1B | $124.7M | $925.5M | $145.3M | $441.6M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.37 (safe)
- Working capital / assets 0.215
- Retained earnings / assets 0.627
- EBIT / assets 0.05
- Equity / liabilities 3.403
Source: SEC EDGAR filings · CIK 0000896264 · as of 2026-01-03. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.